State Street SPDR S&P Pharmaceuticals ETF
XPH
79 hedge funds and large institutions have $172M invested in State Street SPDR S&P Pharmaceuticals ETF in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 14 closing their positions.
12,071% more call options, than puts
Call options by funds: $852K | Put options by funds: $7K
16% more capital invested
Capital invested by funds: $149M → $172M (+$23.9M)
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
4.14% more ownership
Funds ownership: 31.41% → 35.55% (+4.1%)
1% more funds holding
Funds holding: 78 → 79 (+1)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12M |
| 2 |
Goldman Sachs
New York
|
+$11M |
| 3 |
TSS
Two Sigma Securities
New York
|
+$4.82M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.08M |
| 5 |
Citigroup
New York
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$8.15M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$7.89M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$6.59M |
| 4 |
IAA
Ironsides Asset Advisors
Rocky Mount,
North Carolina
|
-$2.76M |
| 5 |
RCM
RNC Capital Management
Los Angeles,
California
|
-$1.83M |
XPH Hedge Fund Activity: Q1 2017 in Review
79 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2017, worth a combined $172M — up 16% from $149M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new XPH positions and 14 closed out — a net gain of 2 holders — while 19 added to existing stakes and 26 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $12M. The largest seller was Barclays, cutting an estimated $8.15M.
- 79 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2017, up from 78 in Q4 2016.
- Funds reported $172M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2017, up 16% quarter-over-quarter.
- 16 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2017 and 14 closed out, a net change of +2 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2017 was Morgan Stanley, an estimated $12M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2017 was Barclays, an estimated $8.15M sold.
Based on aggregated 13F filings for Q1 2017.